Armata Pharmaceuticals (ARMP) Accumulated Expenses (2014 - 2026)

Armata Pharmaceuticals has reported Accumulated Expenses for 13 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Accumulated Expenses rose 108.98% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 108.98% YoY) and the FY2025 annual result came in at $2.2 million, down 3.9% from the prior year.
• Accumulated Expenses rose to $2.8 million in Q1 2026 per ARMP's latest filing, from $2.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.8 million in Q1 2026 and troughed at $768000.0 in Q4 2023.
• A 5-year average of $1.6 million and a median of $1.6 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 57.99% in 2023, then surged 196.88% in 2024.
• Over 5 years, Accumulated Expenses stood at $1.8 million in 2022, then slumped by 57.99% to $768000.0 in 2023, then soared by 196.88% to $2.3 million in 2024, then declined by 3.9% to $2.2 million in 2025, then rose by 28.48% to $2.8 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.8 million, $2.2 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.